[] Genzyme Corporate    [] Genzyme Websites   
Questions? Call 1-888-3-SYNVISC, M–F, 9am–8pm (ET)
Synvisc-One
Synvisc-One™ is the only nonsystemic
therapy delivering up to six months of pain
relief with just one simple injection.1-6
Synvisc
SYNVISC® offers up to six months of OA
knee pain relief with three injections.
Reimbursement Support Synvisc-One and SYNVISC have different reimbursement codes
and processes. SYNVISC ConnectionSM makes it easy to
understand. Access the reimbursement support you need below.

Synvisc-One Reimbursement          SYNVISC Reimbursement
Product Alerts
Stay connected to Synvisc-One and SYNVISC with product alerts,
treatment updates and other important information.

References

1. Synvisc-One Prescribing Information. Cambridge, MA: Genzyme Corp; 2009.
2. Altman RD, Åkermark C, Beaulieu AD, Schnitzer T; Durolane International Study Group. Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2004;12(8):642–649.
3. Post-approval study of Monovisc™, a symptomatic treatment of osteoarthritis. Woburn, MA: Anika Therapeutics, Inc.
4. Durolane Instructions for Use. Memphis, TN: Smith & Nephew, Inc.
5. Brzusek D, Petron D. Treating knee osteoarthritis with intra-articular hyaluronans. Curr Med Res Opin. 2008;24(12):3307–3322.
6. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD005328. doi:10.1002/14651858.CD005328.pub 2.

Important Treatment Considerations

SYNVISC® and Synvisc-One™ (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non pharmacologic therapy and simple analgesics, e.g., acetaminophen.

SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee to be treated.

Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment. Aspiration of any effusion prior to injection is highly recommended. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children or in pregnant or lactating women. It is unknown whether SYNVISC or Synvisc-One is excreted in human milk.

For SYNVISC

In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

View the Complete Prescribing Information for SYNVISC (PDF)

For Synvisc-One

The most commonly reported related local adverse events were transient, mild-to-moderate arthralgia, arthritis, arthropathy, injection site pain and joint effusion. No serious adverse events have been reported in knees injected with Synvisc-One. Repeat treatment did not affect the safety profile. In the pivotal clinical trial, there was one related systemic event of syncope. The most common systemic side effects irrespective of relationship to Synvisc-One were headache, back pain, nasopharyngitis and influenza. Systemic adverse event profiles were similar between patients in the Synvisc-One and Saline Control groups.

View the Complete Prescribing Information for Synvisc-One (PDF)